ライフサイエンスコーパス: transesophageal echocardiogram

1 o had intracardiac vegetations identified by transesophageal echocardiogram.

2 d in 33 patients (28%) on 12-month follow-up transesophageal echocardiogram.

3 ients with cardiac amyloidosis who underwent transesophageal echocardiograms.

4 y due to intracardiac thrombus identified on transesophageal echocardiogram (13 of 16 [81%] vs. 2 of

5 y of stroke/TIA patients with AA atheroma on transesophageal echocardiogram, AA atheroma progression

6 Preprocedure transesophageal echocardiogram and computed tomography/m

7 s had intracardiac vegetations identified by transesophageal echocardiogram, and all underwent percut

8 Of these, 125 consented to a follow-up transesophageal echocardiogram at 12 months.

9 Many centers continue to routinely perform transesophageal echocardiograms before atrial fibrillati

10 ed that the procedures could be done without transesophageal echocardiogram but used intracardiac ech

11 with intracardiac vegetations identified on transesophageal echocardiogram can safely undergo comple

12 Postrepair transesophageal echocardiograms demonstrated mild mitral

13 Preoperative transesophageal echocardiograms demonstrated severe mitr

14 AA atheroma was detected on baseline transesophageal echocardiogram in 167 consecutive patien

15 Transesophageal echocardiograms in 11 patients showed a

16 Transesophageal echocardiogram is a readily available di

17 end-diastolic area (EDA) was calculated from transesophageal echocardiograms obtained during initiati

18 AND PATIENTS: We reviewed the intraoperative transesophageal echocardiograms of 13,092 patients witho

19 graphic features, we analyzed intraoperative transesophageal echocardiograms of 21 consecutive patien

20 METHODS AND We studied all transthoracic and transesophageal echocardiograms of cardiac amyloid patie

21 Ao measurements obtained from intraoperative transesophageal echocardiograms or early (<8 weeks) post

22 All patients (100%) had a transesophageal echocardiogram prior to DCCV.

23 Lung protective strategies, intra-operative transesophageal echocardiogram, pulmonary artery cathete

24 patients (31%) with intracardiac thrombus on transesophageal echocardiogram received adequate anticoa

25 discontinued warfarin therapy if the 45-day Transesophageal echocardiogram revealed either minimal o

26 A transesophageal echocardiogram revealed no vegetations.

27 Transesophageal-echocardiogram revealed thrombus within

28 r, the procedures could be performed without transesophageal echocardiogram screening or intracardiac

29 assess the safety of ablation for AF without transesophageal echocardiogram screening or intracardiac

30 A follow-up transesophageal echocardiogram showed a well seated devi

31 brillation (AF), require a routine screening transesophageal echocardiogram (TEE) before pulmonary ve

32 Transesophageal echocardiogram (TEE) is considered the g

33 Transesophageal echocardiogram (TEE) is generally recomm

34 Transesophageal echocardiogram (TEE) is generally recomm

35 Transesophageal echocardiogram (TEE) on follow-up was do

36 We reviewed reports of 1,288 transesophageal echocardiogram (TEE) studies done with a

37 ation is not well known, yet this may inform transesophageal echocardiogram (TEE) use before cardiove

38 m (TTE) due to relative contraindications to transesophageal echocardiogram (TEE), revealed in a hemo

39 tation for PDL by means of protocol-mandated transesophageal echocardiograms (TEEs) at 45 days and 1

40 in was stopped 3 days before ablation, and a transesophageal echocardiogram was performed to rule out

41 netic resonance (MR) images, angiograms, and transesophageal echocardiograms were also reviewed.

42 Recent modifications included limited transesophageal echocardiogram without anesthesia, avoid